1. Academic Validation
  2. Determination of chrysotoxine in rat plasma by liquid chromatography-tandem mass spectrometry and its application to a rat pharmacokinetic study

Determination of chrysotoxine in rat plasma by liquid chromatography-tandem mass spectrometry and its application to a rat pharmacokinetic study

  • J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Sep 15:967:57-62. doi: 10.1016/j.jchromb.2014.07.011.
Jingjing Fan 1 Li Guan 2 Zeqi Kou 2 Feng Feng 2 Yanbo Zhang 3 Wenyuan Liu 4
Affiliations

Affiliations

  • 1 Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 210009, China.
  • 2 Department of Natural Medicinal Chemistry, China Pharmaceutical University, Nanjing, 210009, China.
  • 3 School of Chinese Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 10 Sassoon Road, Pokfulam, Hong Kong, China. Electronic address: ybzhang@hku.hk.
  • 4 Department of Pharmaceutical Analysis, China Pharmaceutical University, Nanjing, 210009, China. Electronic address: liuwenyuan8506@163.com.
Abstract

Chrysotoxine (CTX), a naturally occurring bibenzyl compound isolated from Dendrobium species, has been reported to have neuroprotective effects. To evaluate its pharmacokinetics in rats, a rapid, sensitive and specific high performance liquid chromatography-tandem mass spectrometric (HPLC-MS/MS) method has been developed and validated for the quantification of CTX in rat plasma. Samples were pretreated using a simple liquid-liquid extraction with ethyl acetate and the chromatographic separation was performed on a C18 column with acetonitrile-water (90:10, v/v) as the mobile phase. CTX and the internal standard (wogonin) were detected using a tandem mass spectrometer in positive multiple reaction monitoring mode. Method validation revealed excellent linearity over the range 0.5-1000 ng/mL together with satisfactory intra- and inter-day precision, accuracy and recovery. Stability testing showed that CTX spiked into rat plasma was stable for 8 h at room temperature, for up to two weeks at -20 °C, and during three freeze-thaw cycles. Extracted samples were also observed to be stable over 24 h in an auto-sampler. The method was successfully used to investigate the pharmacokinetic profile of CTX after oral (100 mg/kg) and intravenous (25 mg/kg) administration in rats. CTX showed rapid excretion and low bioavailability in rats.

Keywords

Bioavailability; Chrysotoxine; HPLC–MS/MS; Method validation; Pharmacokinetics.

Figures
Products